OAK HILL BIO HOLDINGS LIMITED

Oak Hill Bio Holdings Limited is a clinical‑stage biotechnology company dedicated to rescuing promising rare‑disease therapies that have been deprioritised by larger pharmaceutical groups. By acquiring and advancing these assets, the company aims to bring much‑needed treatments to patients who currently have limited options.

The firm’s pipeline currently features two late‑stage candidates. Rugonersen (OHB‑724) is an antisense oligonucleotide designed to address the underlying cause of Angelman syndrome, while mecasermin rinfabate (OHB‑607) is a recombinant human IGF‑1/IGFBP‑3 fusion protein targeting the serious complications of extremely premature birth. In addition, Oak Hill Bio is developing OHB‑401, a plasma kallikrein inhibitor for diabetic macular oedema, further broadening its therapeutic reach.

With a clear focus on rare‑disease drug development, Oak Hill Bio serves patients, caregivers and the wider medical community by translating cutting‑edge science into tangible clinical solutions. Recent publications in *Nucleic Acids Research* and *Nature Medicine* underscore the company’s scientific rigour and its commitment to delivering transformative therapies.